AI summary · may contain errors
In compensated chronic hepatitis D, bulevirtide monotherapy for 144 weeks produced end-of-treatment virologic response rates of 73% (2 mg), 76% (10 mg), and 92% (DT/10), with post-treatment decline.
- Open access
- 19 cites
